Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system.

Objective: To assess the feasibility of clinical pharmacist-led CYP2C19 genotype-guided P2Y inhibitor antiplatelet drug therapy recommendations to cardiologists in an outpatient cardiology practice.

Methods: This was a prospective, open-labeled, single-arm study conducted in an integrated healthcare delivery system between March 1, 2013 and January 23, 2014. Patients requiring non-emergent cardiac catheterization were included.